Evelo Biosciences (NASDAQ:EVLO – Get Free Report) is projected to post its resultson Monday, August 10th. Analysts expect the company to announce earnings of ($10.1333) per share for the quarter.
Evelo Biosciences Price Performance
Shares of NASDAQ:EVLO traded up $0.00 on Monday, reaching $0.00. The company has a market capitalization of $5,652.00, a PE ratio of -0.00 and a beta of 1.78. Evelo Biosciences has a 1 year low of $0.00 and a 1 year high of $0.00.
About Evelo Biosciences
Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered immunomodulatory therapies that leverage the gut-body network. The company’s proprietary platform is designed to mimic signals normally generated by gut commensal bacteria to regulate immune function throughout the body. Evelo’s approach focuses on non-live, inactivated microbial derivatives, aiming to offer a new class of biologics that can be administered by mouth and engage mucosal immune pathways to treat a range of diseases.
The company’s pipeline spans inflammatory, autoimmune and oncology indications.
Further Reading
- Five stocks we like better than Evelo Biosciences
- Large Caps Across Planes, Tech and Oil Announce Over $10 Billion in Buybacks
- A Sweet Beat and a Wearables Rally Came With Reasons to Pause
- 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
